Adenosine A2A receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease

Neuroscience

Volumn 127, Issue 1, 2004, Pages 223-231

  Ochi, M ^a,b   Shiozaki, S ^a   Kase, H ^a,c  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c RIKEN   (Japan)

Author keywords

6 hydroxydopamine; 8 cyclopentyl 1,3 dipropylxanthine; A; adenosine A2A receptor antagonist; anterior; DPCPX; globus pallidus; GP; in vivo microdialysis; KA; kainic acid; KW 6002; striatopallidal neurons; substantia nigra pars reticulata

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; GLUTAMIC ACID; ISTRADEFYLLINE; KAINIC ACID; NEUROTRANSMITTER; OXIDOPAMINE;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; COMPARATIVE STUDY; CONTROLLED STUDY; GLOBUS PALLIDUS; MALE; MICRODIALYSIS; NEUROTRANSMITTER RELEASE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS;

ANIMALS; BASAL GANGLIA; DENERVATION; DISEASE MODELS, ANIMAL; EFFERENT PATHWAYS; EXTRACELLULAR FLUID; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; GLUTAMIC ACID; MALE; MODELS, NEUROLOGICAL; NEOSTRIATUM; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PURINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A; SUBSTANTIA NIGRA;

EID: 1842613894     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2004.04.050     Document Type: Article

References (50)

1. Albin R.L., Young A.B., Penny J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375
2. 2A receptor antagonist treatment of Parkinson's disease. Neurology. 61:2003;293-296
3. Ben-Ari Y., Tremblay E., Ottersen O.P., Naquet R. Evidence suggesting secondary epileptogenic lesions after kainic acid Pre-treatment with diazepam reduces distant but not local brain damage. Brain Res. 165:1979;362-365
4. Benazzouz A., Hallett M. Mechanism of action of deep brain stimulation. Neurology. 55:2000;S13-S16
5. Bergman H., Wichmann T., Karmon B., DeLong M.R. The primate subthalamic nucleus Ii. Neuronal activity in the MPTP model of Parkinsonism. J Neurophysiol. 72:1994;507-520
6. Bevan M.D., Magill P.J., Terman D., Bolam J.P., Wilson C.J. Move to the rhythm Oscillations in the subthalamic nucleus-external globus pallidus network. Trends Neurosci. 25:2002;525-531
7. Chesselet M.F., Delfs J.M. Basal ganglia and movement disorders An update. Trends Neurosci. 19:1996;417-422
8. Chevalier G., Deniau J.M. Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci. 13:1990;277-280
9. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285
10. Deniau J.M., Kitai S.T., Donoghue J.P., Grofova I. Neuronal interactions in the substantia nigra pars reticulata through axon collaterals of the projection neurons. Exp Brain Res. 47:1982;105-113
11. Drew K.L., Ungerstedt U. Pergolide presynaptically inhibits calcium-stimulated release of gamma-aminobutyric acid. J Neurochem. 57:1991;1927-1930
12. Dunwiddie T.V., Masino S.A. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci. 24:2001;31-55
13. Feigin A. Nondopaminergic symptomatic therapies for Parkinson's disease Turn on or turn off? Neurology. 61:2003;286-287
14. Fonnum F., Gottesfeld Z., Grofova I. Distribution of glutamate decarboxylase in the basal ganglia of normal and operated rats Evidence for striato-pallidal striato-entopeduncular and striato-nigral gabaergic fibers. Brain Res. 143:1978;125-138
15. Fuxe K., Stromberg I., Popoli P., Rimondini-Giorgini R., Torvinen M., Ogren S.O., Franco R., Agnati L.F., Ferre S. Adenosine receptors and Parkinson's disease Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv Neurol. 86:2001;345-353
16. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J. Jr, Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432
17. Grace A.A., Bunney B.S. Opposing effects of striatonigral feedback pathways on midbrain dopamine cell activity. Brain Res. 333:1985;271-284
18. 2A receptor antagonist in MPTP-treated monkeys. Neurology. 52:1999;1673-1677
19. Hassani O.-K., Mouroux M., Féger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience. 72:1996;105-115
20. 2A receptor antagonist istradefylline in advanced PD. Neurology. 61:2003;297-303
21. 2A antagonist A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 43:1998;507-513
22. 2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport. 9:1998;2857-2860
23. 2A receptor in basal ganglia. Biosci Biotechnol Biochem. 65:2001;1447-1457
24. 2A receptor selective antagonist KW-6002 Research and development toward a novel nondopaminergic therapy for parkinson's disease. Neurology. 61:2003;S97-S100
25. Kawaguchi Y., Wilson C.J., Emson P.C. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J Neurosci. 10:1990;3421-3438
26. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol. 408:2000;249-255
27. Kornhuber J., Kim J.S., Kornhuber M.E., Kornhuber H.H. The cortico-nigral projection Reduced glutamate content in the substantia nigra following frontal cortex ablation in the rat. Brain Res. 322:1984;124-126
28. Kreiss D.S., Mastropietro C.W., Rawji S.S., Walters J.R. The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson's disease. J Neurosci. 17:1997;6807-6819
29. Lindroth P., Mopper K. High performance liquid chromatography determination of subpicomole amounts of amino acids by precolumn fluorescence derivatization with o-phthaldialdehyde. Anal Chem. 51:1979;1667-1674
30. 2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci. 15:1996;605-611
31. Murer M.G., Riquelme L.A., Tseng K.Y., Pazo J.H. Substantia nigra pars reticulata single unit activity in normal and 60HDA-lesioned rats Effects of intrastriatal apomorphine and subthalamic lesions. Synapse. 27:1997;278-293
32. Nonaka H., Ichimura M. Biochemical characterization of adenosine agonists and antagonists. Kase H., Richardson P.J., Jenner P. Adenosine receptors and Parkinson's disease. 2000;77-105 Academic Press, San Diego
33. 2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine- lesioned rats A microdialysis study. Neuroscience. 100:2000;53-62
34. Ochi M, Shiozaki S, Kase H (2004) L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease. Synapse 52:163-165
35. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 3rd edition :1997;Academic Press, San Diego
36. Plenz D., Kitai S.T. A basal ganglia pacemaker formed by the subthalamic nucleus and external globus pallidus. Nature. 400:1999;677-682
37. Robledo P., Féger J. Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex Electrophysiological data. Brain Res. 518:1990;47-54
38. 2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci. 13:1993;1080-1087
39. 2A receptor enhances GABAA-mediated IPSCs in the rat globus pallidus. J Physiol (Lond). 532:2001;423-434
40. 2A receptors in rats. Neurosci Lett. 352:2003;167-170
41. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology. 147:1999;90-95
42. Smith Y., Bolam J.P. Neurons of the substantia nigra reticulata receive a dense GABA-containing input from the globus pallidus in the rat. Brain Res. 493:1989;160-167
43. Smith Y., Bolam J.P. The output neurones and the dopaminergic neurones of the substantia nigra receive a GABA-containing input from the globus pallidus in the rat. J Comp Neurol. 296:1990;47-64
44. Smith Y., Parent A. Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Res. 453:1988;353-356
45. Smith Y., Bevan M.D., Shink E., Bolam J.P. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience. 86:1998;353-387
46. Takakusaki K., Shiroyama T., Yamamoto T., Kitai S.T. Cholinergic and non-cholinergic tegmental pedunculopontine projection neurons in rats revealed by intracellular labeling. J Comp Neurol. 371:1996;345-361
47. Tseng K.Y., Riquelme L.A., Belforte J.E., Pazo J.H., Murer M.G. Substantia nigra pars reticulata units in 6-hydroxydopamine-lesioned rats Responses to striatal d2 dopamine receptor stimulation and subthalamic lesions. Eur J Neurosci. 12:2000;247-256
48. Ungerstedt U. Post-synaptic supersensitivity after 6-hydroxydopamine degeneration of the nigrostriatal dopamine system. Acta Physiol Scand Suppl. 367:1971;69-93
49. Windels F., Bruet N., Poupard A., Urbain N., Chouvet G., Feuerstein C., Savasta M. Effects of high frequency stimulation of subthalamic nucleus on extracellular glutamate and GABA in substantia nigra and globus pallidus in the normal rat. Eur J Neurosci. 12:2000;4141-4146
50. Wu Y., Richard S., Parent A. The organization of the striatal output system A single-cell juxtacellular labeling study in the rat. Neurosci Res. 38:2000;49-62